Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis


*Indicates shared last authorship

©2018 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2017.182907

Received: October 20, 2017.
Accepted: January 26, 2018.
Pre-published: February 1, 2018.
Correspondence: amato@mskcc.org
Supplementary Figure 1

Time to ibrutinib discontinuation stratified by discontinuation reason

<table>
<thead>
<tr>
<th>Time to ibrutinib discontinuation stratified by discontinuation reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intolerance event</td>
</tr>
<tr>
<td>CLL progression</td>
</tr>
</tbody>
</table>
Supplementary Figure 2

A. Overall survival from ibrutinib start for front-line patients

B. Overall survival from ibrutinib start for relapsed/refractory patients
Supplementary Figure 3

PFS by ibrutinib line of therapy (LOT) in R/R CLL

PFS by Line of Therapy at Relapse in Relapsed/Refractory CLL
Supplementary Figure 4

A. PFS by del17p status in patients with relapsed/refractory CLL

B. PFS by karyotype status in patients with relapsed/refractory CLL
C. PFS by del17p status and karyotype status in patients with relapsed/refractory CLL